Efficacy of Rifaximin in Patients With Small Intestinal Bacterial Overgrowth Presenting With Abdominal Bloating.

Exclusion Criteria

• •1. Pregnant or lactating women.
• •2. History of gastrointestinal malignancy or gastrointestinal surgery.
• •3. Past diagnosis or suspicion of lactose intolerance.
• •4. Confirmed extra-digestive system diseases such as urinary system (chronic kidney disease, etc.), immune system (scleroderma, etc.), nervous system (Parkinson's, etc.), endocrine system (diabetes, etc.).
• •5. Abnormalities in professional anxiety and depression symptom rating scales.
• •6. Use of antibiotics, probiotics within two weeks, endoscopic examination, or use of prokinetics, secretagogues, antifoaming agents, antispasmodics, opioids, antidepressants within one week.
• •7. Those who cannot or are unwilling to sign an informed consent form.
• •Patient Group:
• •1. Pregnant or lactating women.
• •2. History of gastrointestinal malignancy or gastrointestinal surgery.
• •3. Past diagnosis or suspicion of lactose intolerance.
• •4. Confirmed extra-digestive system diseases such as urinary system (chronic kidney disease, etc.), immune system (scleroderma, etc.), nervous system (Parkinson's, etc.), endocrine system (diabetes, etc.).
• •5. Moderate to severe abnormalities in professional anxiety and depression symptom rating scales.
• •6. Use of antibiotics, probiotics within two weeks, endoscopic examination, or use of prokinetics, secretagogues, antifoaming agents, antispasmodics, opioids, antidepressants within one week.
• •7. Those who cannot or are unwilling to sign an informed consent form.